Skip to content

Prognosis Scoring System for Acute-on-Chronic Liver Failure

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01961440
Enrollment
1000
Registered
2013-10-11
Start date
2013-10-31
Completion date
Unknown
Last updated
2013-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Failure

Brief summary

This research is to establish a simple and practical system to predict the prognosis of sever hepatitis B.Seven factors (level of serum total bilirubin, prothrombin time, severity of hepatic encephalopathy, hepatorenal syndrome,ascites ,infection and size of liver) which were easier to evaluate and more influential, were included to establish a prognosis scoring system.The scorings of a new score system and MELD were graded at the same time in the patients with sever hepatitis B. And then the distribution figures of survival rates and mortality rates were done according to the scores from low to high. The features of distribution figures of two score system in survival rates and mortality rates and significances of clinical application in certain score were interpreted.

Interventions

None listed

Sponsors

Third Affiliated Hospital, Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* serum hepatitis B surface antigen(HBsAg) positive for at least 6 months; * All patients had a poor general condition, manifested as general malaise, fatigue, jaundice and so on; * serum T-Bil of 171 mmol/L or more; or serum T-Bil rises 17.1 mmol/L or more per day;

Exclusion criteria

* superinfection or co-infection with hepatitis A, C, D, E, cytomegalovirus and HIV, or Epstein-Barr virus; * other liver diseases such as alcoholic liver disease, drug-induced hepatitis, Wilson disease and autoimmune hepatitis; * ascites or gastrointestinal bleeding or peptic ulcer or esophageal varix by electronic gastroscope examination; * decompensated liver cirrhosis; * severe bacterial or fungal infections; * a history of diabetes or cardiac disease or hypertension or nephrosis.

Design outcomes

Primary

MeasureTime frame
survival ratetwelve weeks

Contacts

Primary Contactzhe-bin wu
wzbice1982@sohu.com13751743264

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026